Meftal%25252525252525252525252525252525252525252525252525252525252525252525252525252520spas

# Meftal spas ## Overview Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent. Mefenamic acid inhibits prostaglandin synthesis, reducing inflammation and pain. Hyoscine butylbromide works peripherally to block muscarinic receptors, reducing gastrointestinal smooth muscle spasms. ## Primary Indications * Symptomatic relief of abdominal pain and cramps associated with gastrointestinal disorders. * Management of primary dysmenorrhea. ## Adult Dosing * **Abdominal Pain/Cramps:** 1 tablet (250 mg mefenamic acid / 10 mg hyoscine butylbromide) orally every 8 hours as needed. Do not exceed 3 tablets in 24 hours. * **Primary Dysmenorrhea:** 1 tablet (250 mg mefenamic acid / 10 mg hyoscine butylbromide) orally every 8 hours, starting at the onset of pain and continuing for up to 3 days. ## Pediatric Dosing Dosing for pediatric patients is not well-established for this combination product. Mefenamic acid pediatric dosing is typically based on weight, but hyoscine butylbromide dosing in children is less commonly prescribed and varies. Consult specific pediatric guidelines or specialist advice. ## Dose Adjustments * **Renal Impairment:** Use with caution. Mefenamic acid is renally cleared; severe impairment may require dose reduction or avoidance. * **Hepatic Impairment:** Use with caution. Mefenamic acid is metabolized in the liver; severe impairment may require dose reduction or avoidance. * **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding and renal events. Use with caution and at the lowest effective dose. ## Contraindications * Known hypersensitivity to mefenamic acid, hyoscine butylbromide, or other NSAIDs. * History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. * Active or history of recurrent peptic ulceration or gastrointestinal bleeding. * Severe renal, hepatic, or cardiac impairment. * Myasthenia gravis. * Tachyarrhythmias. * Obstructive uropathy or obstructive gastrointestinal conditions. * Acute glaucoma. * Prostatic hypertrophy with urinary retention. * Last trimester of pregnancy. ## Adverse Effects **Common:** * Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia. * Central Nervous System: Dizziness, headache, drowsiness. * Anticholinergic (Hyoscine): Dry mouth, blurred vision, urinary retention, constipation, tachycardia. **Serious:** * Gastrointestinal: Ulceration, bleeding, perforation. * Cardiovascular: Increased risk of myocardial infarction, stroke, hypertension. * Renal: Renal papillary necrosis, interstitial nephritis, renal failure. * Hepatic: Hepatotoxicity. * Hematologic: Anemia, leukopenia, thrombocytopenia. * Hypersensitivity: Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis. ## Key Drug Interactions * **Other NSAIDs, Aspirin, Corticosteroids, SSRIs:** Increased risk of gastrointestinal bleeding. * **Anticoagulants (e.g., Warfarin), Antiplatelets:** Increased risk of bleeding. * **Lithium, Methotrexate:** Increased serum levels and toxicity. * **ACE Inhibitors, ARBs, Diuretics:** Reduced antihypertensive effect and increased risk of renal impairment. * **Beta-blockers, Guanethidine:** Reduced antihypertensive effect. * **Antacids:** May decrease absorption of mefenamic acid. * **Anticholinergics:** Additive anticholinergic effects with hyoscine component. ## Monitoring * **Renal Function:** Baseline and periodic monitoring, especially in patients with pre-existing renal disease or those on concomitant nephrotoxic agents. * **Hepatic Function:** Baseline and periodic monitoring, especially in patients with pre-existing hepatic disease. * **Gastrointestinal Symptoms:** Monitor for signs of bleeding (melena, hematemesis) or ulceration. * **Blood Pressure:** Monitor for hypertension, particularly in patients with pre-existing hypertension. * **Signs of Anticholinergic Effects:** Monitor for dry mouth, blurred vision, urinary retention. ## Clinical Pearls * This combination aims to treat both the inflammatory/pain component (mefenamic acid) and the smooth muscle spasm component (hyoscine butylbromide) of abdominal pain. * Due to the potential for serious gastrointestinal and cardiovascular adverse effects, use the lowest effective dose for the shortest duration necessary. * Administer with food or milk to minimize gastrointestinal upset. * Avoid concomitant use with other NSAIDs. * Be cautious in patients with a history of asthma, as NSAIDs can trigger bronchospasm. * The anticholinergic effects of hyoscine butylbromide can be problematic in the elderly or those with certain medical conditions (e.g., glaucoma, urinary retention). *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information with the official product monograph or a trusted drug reference before making any clinical decisions. Dosing and recommendations may vary based on patient-specific factors and local protocols.